TMEM158 and FBLP1 as novel marker genes of cisplatin sensitivity in non-small cell lung cancer cells

REFERENCES

• Bareschino MA, Schettino C, Rossi A, Maione P, Sacco PC, Zeppa R, Gridelli C: Treatment of advanced non small cell lung cancer. J Thorac Dis. 2011;3:122–133.
   Google Scholar
• Gaughan EM, Costa DB: Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. Ther Adv Med Oncol. 2011;3:113–125.
   PubMedGoogle Scholar
• Varughese S, Jahangir KS, Simpson CE, Boulmay BC, Lopez F: A paradigm shift in the treatment of advanced non-small cell lung cancer. Am J Med Sci. 2012;344:147–150.
   PubMedGoogle Scholar
• Jemal A, Siegel R, Xu J, Ward E: Cancer statistics. CA Cancer J Clin. 2010;60:277–300.
   PubMed Web of Science ®Google Scholar
• Youlden DR, Cramb SM, Baade PD: The international epidemiology of lung cancer: geographical distribution and secular trends. J Thorac Oncol. 2008;3:819–831.
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH: Eastern Cooperative Oncology Group: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–98.
   PubMed Web of Science ®Google Scholar
• NSCLC Meta-Analysis Collaborative Group: Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26:4617–4625.
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Jahan T, Jahanzeb M, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Simon GR, Swanson SJ, Wood DE, Yang SC; NCCN Non-Small Cell Lung Cancer Panel Members: Non-small cell lung cancer. J Natl Compr Canc Netw. 2010;8:740–801.
   PubMed Web of Science ®Google Scholar
• Azzoli CG, Temin S, Aliff T, Baker S Jr, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pao W, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G: 2011 Focused update of 2009 American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2011;29:3825–3831.
   PubMed Web of Science ®Google Scholar
• Evans WE, Relling MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286:487–491.
   PubMed Web of Science ®Google Scholar
• McLeod HL, Evans WE: Pharmacogenomics: unlocking the human genome for better drug therapy. Ann Rev Pharmacol Toxicol. 2001;41:101–121.
   PubMed Web of Science ®Google Scholar
• Gibbs JB: Mechanism-based target identification and drug discovery in cancer research. Science. 2000;287: 1969–1973.
   PubMed Web of Science ®Google Scholar
• Nishiyama M, Eguchi H: Recent advances in cancer chemotherapy: current strategies, pharmacokinetics, and pharmacogenomics. Adv Drug Deliv Rev. 2009;6:367–368.
   Google Scholar
• Langer CJ: Individualized therapy for patients with non-small cell lung cancer: emerging trends and challenges. Crit Rev Oncol Hematol. 2012;83:130–144.
   PubMed Web of Science ®Google Scholar
• Pérez-Soler R: Individualized therapy in non-small-cell lung cancer: future versus current clinical practice. Oncogene. 2009;28 (Suppl 1):S38–S45.
   PubMedGoogle Scholar
• Hildebrandt MA, Gu J, Wu X: Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metab Toxicol. 2009;5:745–55.
   PubMed Web of Science ®Google Scholar
• Danesi R, Pasqualetti G, Giovannetti E, Crea F, Altavilla G, Del Tacca M, Rosell R: Pharmacogenomics in non-small-cell lung cancer chemotherapy. Adv Drug Deliv Rev. 2009;61:408–417.
   PubMed Web of Science ®Google Scholar
• Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D: Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. 2009;9:489–499.
   PubMed Web of Science ®Google Scholar
• Ohtaki M, Otani K, Satoh K, Kawamura T, Hiyama K Nishiyama M: Model-based analysis of microarray data: exploration of differentially expressed genes between two cell types based on a two-dimensional mixed normal model. Jpn J Biometrics. 2005;26:31–48.
   Google Scholar
• Hong WS, Saijo N, Sasaki Y, Minato K, Nakano H, Nakagawa K, Fujiwara Y, Nomura K, Twentyman PR: Establishment and characterization of cisplatin-resistant sublines of human lung cancer cell lines. Int J Cancer. 1988;41:462–467.
   PubMed Web of Science ®Google Scholar
• Komatsu M, Hiyama K, Tanimoto K, Yunokawa M, Otani K, Ohtaki M, Hiyama E, Kigawa J, Ohwada M, Suzuki M, Nagai N, Kudo Y, Nishiyama M: Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers. Mol Cancer Ther. 2006;5:767–775.
   PubMed Web of Science ®Google Scholar
• Rousseau PJ: Least median of squares regression. J Am Stat Assoc. 1984;79:871–880.
   Web of Science ®Google Scholar
• R Development Core Team: R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2010 ISBN 3–900051-07–0, URL http://www.R-project.org/.
   Google Scholar
• Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC: DNA repair by ERCC1 in nonsmall-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983–991.
   PubMed Web of Science ®Google Scholar
• Postel-Vinay S, Vanhecke E, Olaussen KA, Lord CJ, Ashworth A, Soria JC: The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nat Rev Clin Oncol. 2012;9:144–155.
   PubMed Web of Science ®Google Scholar
• Jiang J, Liang X, Zhou X, Huang R, Chu Z, Zhan Q: ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis. Mol Biol Rep. 2012;39:6933–6942.
   PubMed Web of Science ®Google Scholar
• Pierceall WE, Olaussen KA, Rousseau V, Brambilla E, Sprott KM, Andre F, Pignon JP, Le Chevalier T, Pirker R, Jiang C, Filipits M, Chen Y, Kutok JL, Weaver DT, Ward BE, Soria JC: Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses. Ann Oncol. 2012;23:2245–2252.
   PubMed Web of Science ®Google Scholar
• Calvo SE, Tucker EJ, Compton AG, Kirby DM, Crawford G, Burtt NP, Rivas M, Guiducci C, Bruno DL, Goldberger OA, Redman MC, Wiltshire E, Wilson CJ, Altshuler D, Gabriel SB, Daly MJ, Thorburn DR, Mootha VK: High-throughput, pooled sequencing identifies mutations in NUBPL and FOXRED1 in human complex I deficiency. Nat Genet. 2010;42:851–858.
   PubMed Web of Science ®Google Scholar
• Sheftel AD, Stehling O, Pierik AJ, Netz DJ, Kerscher S, Elsässer HP, Wittig I, Balk J, Brandt U, Lill R: Human ind1, an iron-sulfur cluster assembly factor for respiratory complex I. Mol Cell Biol. 2009;29:6059–6073.
   PubMed Web of Science ®Google Scholar
• Bych K, Kerscher S, Netz DJ, Pierik AJ, Zwicker K, Huynen MA, Lill R, Brandt U, Balk J: The iron-sulphur protein Ind1 is required for effective complex I assembly. EMBO J. 2008;27:1736–1746.
   PubMed Web of Science ®Google Scholar
• Basit S, Ali G, Wasif N, Ansar M, Ahmad W: Genetic mapping of a novel hypotrichosis locus to chromosome 7p21.3-p22.3 in a Pakistani family and screening of the candidate genes. Hum Genet. 2010;128:213–220.
   PubMed Web of Science ®Google Scholar
• Huang YC, Schmitt M, Yang Z, Que LG, Stewart JC, Frampton MW, Devlin RB: Gene expression profile in circulating mononuclear cells after exposure to ultrafine carbon particles. Inhal Toxicol. 2010;22:835–846.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zhou L, Liu B, Deng Y, Wang Y, Wang Y, Huang W, Yuan W, Wang Z, Zhu C, Liu M, Wu X, Li Y: ZNF325, a novel human zinc finger protein with a RBaK-like RB-binding domain, inhibits AP-1- and SRE-mediated transcriptional activity. Biochem Biophys Res Commun. 2006;346:1191–1199.
   PubMed Web of Science ®Google Scholar
• Song Q, Jing H, Wu H, Zhou G, Kajiyama T, Kambara H: Gene expression analysis on a photodiode array-based bioluminescence analyzer by using sensitivity-improved SRPP. Analyst. 2010;135:1315–1319.
   PubMed Web of Science ®Google Scholar
• Takafuta T, Saeki M, Fujimoto TT, Fujimura K, Shapiro SS: A new member of the LIM protein family binds to filamin B and localizes at stress fibers. J Biol Chem. 2003;278:12175–12181.
   PubMed Web of Science ®Google Scholar
• Tu Y, Wu S, Shi X, Chen K, Wu C: Migfilin and Mig-2 link focal adhesions to filamin and the actin cytoskeleton and function in cell shape modulation. Cell. 2003;113:37–47.
   PubMed Web of Science ®Google Scholar
• Wu C: Migfilin and its binding partners: from cell biology to human diseases. J Cell Sci. 2005;118(Pt 4):659–664.
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhang Y, Ithychanda SS, Tu Y, Chen K, Qin J, Wu C: Migfilin interacts with Src and contributes to cell-matrix adhesion-mediated survival signaling. J Biol Chem. 2009;284:34308–34320.
   PubMed Web of Science ®Google Scholar
• Chou CH, Chou AK, Lin CC, Chen WJ, Wei CC, Yang MC, Hsu CM, Lung FW, Loh JK, Howng SL, Hong YR: GSK3β regulates Bcl2L12 and Bcl2L12A anti-apoptosis signaling in glioblastoma and is inhibited by LiCl. Cell Cycle. 2012;11:532–542.
   PubMed Web of Science ®Google Scholar
• Doble BW, Woodgett JR: GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 2003;116:1175–1186.
   PubMed Web of Science ®Google Scholar
• Grimes CA, Jope RS: The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Pro Neurobiol. 2001;65:391–426.
   PubMed Web of Science ®Google Scholar
• Zhang D, Guo M, Zhang W, Lu XY: Adiponectin stimulates proliferation of adult hippocampal neural stem/progenitor cells through activation of p38 mitogen-activated protein kinase (p38MAPK)/glycogen synthase kinase 3β (GSK-3β)/β-catenin signaling cascade. J Biol Chem. 2011;286:44913–44920.
   PubMed Web of Science ®Google Scholar
• Beurel E, Kornprobst M, Blivet-Van Eggelpoël MJ, Ruiz-Ruiz C, Cadoret A, Capeau J, Desbois-Mouthon C: GSK-3beta inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas/APO-1) expression. Exp Cell Res. 2004;300:354–364.
   PubMed Web of Science ®Google Scholar
• Dong J, Peng J, Zhang H, Mondesire WH, Jian W, Mills GB, Hung MC, Meric-Bernstam F: Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. Cancer Res. 2005;65:1961–1972.
   PubMed Web of Science ®Google Scholar
• Ding Q, He X, Hsu JM, Xia W, Chen CT, Li LY, Lee DF, Liu JC, Zhong Q, Wang X, Hung MC: Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol. 2007;27:4006–4017.
   PubMedGoogle Scholar
• Kwok JB, Loy CT, Hamilton G, Lau E, Hallupp M, Williams J, Owen MJ, Broe GA, Tang N, Lam L, Powell JF, Lovestone S, Schofield PR: Glycogen synthase kinase-3beta and tau genes interact in Alzheimer's disease. Ann Neurol. 2008;64:446–454.
   PubMed Web of Science ®Google Scholar
• Barradas M, Gonos ES, Zebedee Z, Kolettas E, Petropoulou C, Delgado MD, León J, Hara E, Serrano M. Marta Barradas, Efstathios S.Gonos: Identification of a candidate tumor-suppressor gene specifically activated during Ras-induced senescence. Exp Cell Res. 2002;273:127–137.
   PubMed Web of Science ®Google Scholar
• Silva J, Silva JM, Barradas M, García JM, Domínguez G, García V, Peña C, Gallego I, Espinosa R, Serrano M, Bonilla F: Analysis of the candidate tumor suppressor Ris-1 in primary human breast carcinomas. Mutat Res. 2006;594:78–85.
   PubMed Web of Science ®Google Scholar
• Birch AH, Quinn MC, Filali-Mouhim A, Provencher DM, Mes-Masson AM, Tonin PN: Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes. Mol Carcinog. 2008;47:56–65.
   PubMed Web of Science ®Google Scholar
• Iglesias D, Fernández-Peralta AM, Nejda N, Daimiel L, Azcoita MM, Oliart S, González-Aguilera JJ: RIS1, a gene with trinucleotide repeats, is a target in the mutator pathway of colorectal carcinogenesis. Cancer Genet Cytogenet. 2006;167: 138–144.
   PubMed Web of Science ®Google Scholar
• Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, Lynch TJ, Neuberg DS, Christiani DC: XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol. 2004;22:2594–2601.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Tanimoto K, Otani K, Satoh K, Ohtaki M, Yoshida K, Toge T, Yahata H, Tanaka S, Chayama K, Okazaki Y, Hayashizaki Y, Hiyama K, Nishiyama M: Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer. 2004;111:617–626.
   PubMed Web of Science ®Google Scholar
• Ichikawa W, Takahashi T, Suto K, Shirota Y, Nihei Z, Shimizu M, Sasaki Y, Hirayama R: Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int J Cancer. 2006;119:1927–1933.
   PubMed Web of Science ®Google Scholar
• Shimizu J, Horio Y, Osada H, Hida T, Hasegawa Y, Shimokata K, Takahashi T, Sekido Y, Yatabe Y: mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines. Respirology. 2008;13:510–517.
   PubMed Web of Science ®Google Scholar
• Singh S, Okamura T, Ali-Osman F: Serine phosphorylation of glutathione S-transferase P1 (GSTP1) by PKCα enhances GSTP1-dependent cisplatin metabolism and resistance in human glioma cells. Biochem Pharmacol. 2010;80:1343–1355.
   PubMed Web of Science ®Google Scholar
• Okamura T, Singh S, Buolamwini J, Haystead T, Friedman H, Bigner D, Ali-Osman F: Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor. J Biol Chem. 2009;284:16979–16989.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhu J, Xing R, Tie Y, Fu H, Zheng X, Yu B: miR-513a-3p sensitizes human lung adenocarcinoma cells to chemotherapy by targeting GSTP1. Lung Cancer. 2012;77:488–494.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhong M, Liu W, Li J, Huang J, Zheng L: Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp Lung Res. 2011;37:427–434.
   PubMed Web of Science ®Google Scholar
• Ballou LM, Lin RZ: Rapamycin and mTOR kinase inhibitors. J Chem Biol. 2008;1:27–36.
   PubMedGoogle Scholar
• Moyer AM, Salavaggione OE, Wu TY, Moon I, Eckloff BW, Hildebrandt MA, Schaid DJ, Wieben ED, Weinshilboum RM: Glutathione s-transferase p1: gene sequence variation and functional genomic studies. Cancer Res. 2008;68:4791–4801.
   PubMed Web of Science ®Google Scholar
• Fumoto S, Shimokuni T, Tanimoto K, Hiyama K, Otani K, Ohtaki M, Hihara J, Yoshida K, Hiyama E, Noguchi T, Nishiyama M: Selection of a novel drug-response predictor in esophageal cancer: a novel screening method using microarray and identification of IFITM1 as a potent marker gene of CDDP response. Int J Oncol. 2008;32:413–423.
   PubMed Web of Science ®Google Scholar